James Hattersley

Mr. James Hattersley has over 25 years of successful leadership experience in biotech and pharmaceutical life science industries.

In his current role, since joining Nektar in May 2014, Mr. Hattersley leads a team of experts focused on growth opportunities in oncology and pain management.  Key objectives include successful late stage development and establishing strategic commercial partnerships.  Prior to Nektar, from 1995 to May 2014, Mr. Hattersley executed several high-value asset and technology transactions at Eurand, Antares, and Sun Pharma.  Regarding R&D background, from 1986 to 1995, Mr. Hattersley developed specialty drug delivery and NCE products at both Alza and Abbott.  

Mr. Hattersley attended The University of Chicago Booth School of Business, and received undergraduate and graduate degrees in Neurobiology and Biochemistry, respectively, both from The University of California.